Research
Hormonal
SGLT-2 inhibitors and GLP-1 receptor agonists are effective in cardiovascular disease prevention among those with diabetes, heart failure, and chronic kidney disease.
Healthcare providers should consider these agents for patients with diabetes and related cardiovascular conditions.
StrongSupportsmedium confidence
Several landmark trials have demonstrated the efficacy of these novel agents, not only in cardiovascular disease prevention among those with diabetes, but also in heart failure and chronic kidney disease.
Why this rating
Based on landmark trials mentioned in the abstract.
Source
Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
Apurva Khedagi et al. · American Journal of Preventive Cardiology · 2023
DOI 10.1016/j.ajpc.2023.100477
reviewCited 24×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →